174 related articles for article (PubMed ID: 34931443)
1. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes.
Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB
Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443
[TBL] [Abstract][Full Text] [Related]
2. Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients.
Danese MD; Lubeck D; Belozeroff V; Lin TC; Desai P; Gleeson M; Martin K; Chonchol M
Am J Nephrol; 2020; 51(10):815-822. PubMed ID: 32966995
[TBL] [Abstract][Full Text] [Related]
3. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
4. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness.
Karaboyas A; Muenz D; Hwang Y; Goodman W; Cheng S; Desai P; Fox KM; Robinson BM; Pisoni RL
Kidney Med; 2022 Jun; 4(6):100475. PubMed ID: 35637925
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
6. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
7. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Friedl C; Zitt E
Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Goodman WG; Ward DT; Martin KJ; Drayer D; Moore C; Xu J; Lai J; Chon Y; Nemeth EF
J Am Soc Nephrol; 2022 Jan; 33(1):201-212. PubMed ID: 34732508
[TBL] [Abstract][Full Text] [Related]
9. Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study.
Morosetti M; Jankovic L; Zappalà L; Agafonova E; Pryshlyak I
Int Urol Nephrol; 2023 Jul; 55(7):1865-1873. PubMed ID: 36790677
[TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Eidman KE; Wetmore JB
Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
[TBL] [Abstract][Full Text] [Related]
11. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
[TBL] [Abstract][Full Text] [Related]
12. Etelcalcetide for the treatment of secondary hyperparathyroidism.
Hamano N; Komaba H; Fukagawa M
Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical Management of Secondary Hyperparathyroidism and the Role of Surgery: A 5-Year Retrospective Study.
Sevva C; Divanis D; Tsinari A; Grammenos P; Laskou S; Mantalobas S; Paschou E; Magra V; Kopsidas P; Kesisoglou I; Liakopoulos V; Sapalidis K
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792994
[No Abstract] [Full Text] [Related]
14. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
Dudar I; Shifris I; Dudar S; Kulish V
Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
[TBL] [Abstract][Full Text] [Related]
16. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
[TBL] [Abstract][Full Text] [Related]
17. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
[TBL] [Abstract][Full Text] [Related]
18. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics.
Arenas MD; Rodelo-Haad C; de Mier MVP; Rodriguez M
Clin Kidney J; 2021 Mar; 14(3):840-846. PubMed ID: 33777366
[TBL] [Abstract][Full Text] [Related]
19. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
20. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]